A Novel Polyacrylamide Magnetic Nanoparticle Contrast Agent for Molecular Imaging using MRI
Autor: | Alnawaz Rehemtulla, G. Ramachandra Reddy, Raoul Kopelman, Martin A. Philbert, Brian D. Ross, Thomas L. Chenevert, Daniel E. Hall, Patrick McConville, Ralph Weissleder, Bradford A. Moffat |
---|---|
Rok vydání: | 2003 |
Předmět: |
Male
lcsh:Medical technology MRI contrast agent Polyacrylamide Acrylic Resins Biomedical Engineering Iron oxide Contrast Media Nanoparticle Polyethylene glycol Polyethylene Glycols Matrix (chemical analysis) chemistry.chemical_compound Nuclear magnetic resonance Tumor Cells Cultured medicine Animals Nanotechnology Radiology Nuclear Medicine and imaging Particle Size lcsh:QH301-705.5 medicine.diagnostic_test Brain Neoplasms Magnetic resonance imaging Condensed Matter Physics Magnetic Resonance Imaging Rats Inbred F344 Rats lcsh:Biology (General) lcsh:R855-855.5 chemistry Biophysics Molecular Medicine Molecular imaging Half-Life Biotechnology |
Zdroj: | Molecular Imaging, Vol 2 (2003) |
ISSN: | 1536-0121 1535-3508 |
DOI: | 10.1162/153535003322750664 |
Popis: | A novel polyacrylamide superparamagnetic iron oxide nanoparticle platform is described which has been synthetically prepared such that multiple crystals of iron oxide are encapsulated within a single polyacrylamide matrix ( PolyAcrylamide Magnetic [PAM] nanoparticles). This formulation provides for an extremely large T2 and T2* relaxivity of between 620 and 1140 sec � 1 mM � 1 . Administration of PAM nanoparticles into rats bearing orthotopic 9L gliomas allowed quantitative pharmacokinetic analysis of the uptake of nanoparticles in the vasculature, brain, and glioma. Addition of polyethylene glycol of varying sizes (0.6, 2, and 10 kDa) to the surface of the PAM nanoparticles resulted in an increase in plasma half-life and affected tumor uptake and retention of the nanoparticles as quantified by changes in tissue contrast using MRI. The flexible formulation of these nanoparticles suggests that future modifications could be accomplished allowing for their use as a targeted molecular imaging contrast agent and/or therapeutic platform for multiple indications. Mol Imaging (2003) 2, 324 – 332. |
Databáze: | OpenAIRE |
Externí odkaz: |